Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of Azenosertib (ZN-c3) in participants with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Azenosertib (azenosertib)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED